Danish cancer specialist Genmab (OMX: GEN) has announced positive top-line results from the Phase III ANDROMEDA study of subcutaneous (SC) daratumumab.
Janssen Biotech, a subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ), has been developing the product under the terms of global agreement reached in 2012.
Approved and marketed as Darzalex in its original formulation, the therapy is already having a significant impact, generating first quarter 2020 sales of $937 million, up 49% from the same period of 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze